Minocycline in Alzheimer's disease

INTERVENTION: Drug Treatment. Participants will be allocated to one of three treatment arms: 1. Minocycline 400mg/day 2. Minocycline 200mg/day 3. Placebo They will take the allocated treatment orally for a period of two years. CONDITION: Topic: Dementias and Neurodegenerative Diseases Research Network; Subtopic: Dementia; Disease: Alzheimer's Disease ; Nervous System Diseases ; Alzheimer disease PRIMARY OUTCOME: To determine whether minocycline is superior to placebo; Timepoint(s): Baseline and 2 years; 1. Cognition will be measured using sMMSE; 2. Functional ability will be measured using Bristol Activities of Daily Living Scale (BADLS) SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 1. Diagnosis by National Institute on Aging (NIA)/ Alzheimer's Association (AA) criteria of possible or probable Alzheimer's Disease (McKhann et al 2011) 2. Standardized Mini‐Mental State Examination (SMMSE) score >23 with no upper limit 3. Consenting to participate Target Gender: Male & Female; Upper Age Limit 100 no age limit or unit specified ; Lower Age Limit 45 no age limit or unit specified